Related Experiment Videos
Excitatory amino acids: implications for psychiatric disorders research
M Toru1, A Kurumaji, M Ishimaru
1Department of Neuropsychiatry, Tokyo Medical and Dental University School of Medicine, Japan.
Life Sciences
|January 1, 1994
Summary
The hyperdopaminergic theory inadequately explains schizophrenia, particularly negative symptoms. This review explores excitatory amino acid (EAA) roles and potential new treatments targeting glutamate pathways in schizophrenia.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- The hyperdopaminergic theory of schizophrenia has limitations, failing to explain negative symptoms or chronic deterioration.
- Schizophrenia involves complex neurochemical imbalances beyond dopamine.
Purpose of the Study:
- To review the interactions between dopamine and excitatory amino acid (EAA) neurons in abnormal behavior.
- To examine the influence of psychotropic drugs on EAA systems.
- To discuss the hypoglutamate hypothesis of schizophrenia.
Main Methods:
- Literature review of studies on dopamine-EAA interactions.
- Analysis of drug effects (phencyclidine, amphetamines, antipsychotics, antidepressants, anxiolytics) on EAA.
- Tabulation of glutamate receptor data from postmortem schizophrenic brains.
Main Results:
- Dopamine and EAA neuron interactions contribute to abnormal behaviors.
- Phencyclidine supports the hypoglutamate theory; EAAs are involved in amphetamine sensitization.
- Various psychotropic drugs interact with EAA systems, suggesting new therapeutic targets.
Conclusions:
- The hypoglutamate hypothesis offers a broader explanation for schizophrenia, especially negative symptoms.
- Targeting EAA systems presents a promising avenue for novel psychotropic drug development.
- Further research into glutamate receptor function in schizophrenia is warranted.